PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 23061411-7 2012 Moreover, METH-induced impairment in memory performance and AKT/mammalian target of rapamycin pathway were both prevented by the Y(2) receptor antagonist, BIIE0246. BIIE 0246 156-164 AKT serine/threonine kinase 1 Homo sapiens 60-63 23396168-7 2013 The protective effects of NPY on spatial memory of Abeta1-40-treated mice were abolished by the pretreatment with the selective Y2 receptor antagonist BIIE0246. BIIE 0246 151-159 neuropeptide Y Mus musculus 26-29 23396168-7 2013 The protective effects of NPY on spatial memory of Abeta1-40-treated mice were abolished by the pretreatment with the selective Y2 receptor antagonist BIIE0246. BIIE 0246 151-159 neuropeptide Y receptor Y2 Mus musculus 128-139 23061411-7 2012 Moreover, METH-induced impairment in memory performance and AKT/mammalian target of rapamycin pathway were both prevented by the Y(2) receptor antagonist, BIIE0246. BIIE 0246 156-164 mechanistic target of rapamycin kinase Homo sapiens 64-93 21823118-8 2012 Using NPY receptor antagonists (Y1R:BIBP3226, Y2R:BIIE0246 and Y5R:L-152,804), we found the proliferative response to be Y5R mediated. BIIE 0246 50-58 neuropeptide Y Mus musculus 6-9 23061411-7 2012 Moreover, METH-induced impairment in memory performance and AKT/mammalian target of rapamycin pathway were both prevented by the Y(2) receptor antagonist, BIIE0246. BIIE 0246 156-164 neuropeptide Y receptor Y2 Mus musculus 129-143 22981159-7 2012 Adipocytes were incubated with NPY (100nM) and a decrease on lipid accumulation and PPAR-gamma expression was observed in the presence of NPY Y(2) receptor antagonist (BIIE0246, 1muM) or NPY Y(5) antagonist. BIIE 0246 168-176 peroxisome proliferator activated receptor gamma Mus musculus 84-94 22981159-7 2012 Adipocytes were incubated with NPY (100nM) and a decrease on lipid accumulation and PPAR-gamma expression was observed in the presence of NPY Y(2) receptor antagonist (BIIE0246, 1muM) or NPY Y(5) antagonist. BIIE 0246 168-176 neuropeptide Y receptor Y2 Mus musculus 138-155 22903826-8 2012 Food intake experiments using the NPY2 receptor antagonist BIIE0246 and the CCK1A receptor antagonist devazepide, individually, suggested that PYY mediated DON-induced anorexia but CCK did not. BIIE 0246 59-67 peptide YY Homo sapiens 143-146 21692185-2 2011 As part of a project focused on the search for guanidine bioisosteres, argininamide-type neuropeptide Y (NPY) Y2 receptor (Y2R) antagonists related to BIIE0246 were synthesized. BIIE 0246 151-159 neuropeptide Y receptor Y2 Homo sapiens 89-121 18005069-6 2007 NPY was administered intracerebroventricularly, intrahippocampally via the microdialysis probe, or coadministered intrahippocampally with the D2 receptor antagonist remoxipride, the Y2 receptor antagonist BIIE0246 or the sigma 1 receptor antagonist BD1047. BIIE 0246 205-213 neuropeptide Y Rattus norvegicus 0-3 20676138-6 2010 In vitro, Y2R antagonist (BIIE0246) prevented activation of p44/42 mitogen-activated protein kinase (MAPK) induced by endogenous NPY, which resulted in decreased proliferation and induction of Bim-mediated apoptosis. BIIE 0246 26-34 interferon induced protein 44 Homo sapiens 60-63 20676138-6 2010 In vitro, Y2R antagonist (BIIE0246) prevented activation of p44/42 mitogen-activated protein kinase (MAPK) induced by endogenous NPY, which resulted in decreased proliferation and induction of Bim-mediated apoptosis. BIIE 0246 26-34 neuropeptide Y Homo sapiens 129-132 20676138-6 2010 In vitro, Y2R antagonist (BIIE0246) prevented activation of p44/42 mitogen-activated protein kinase (MAPK) induced by endogenous NPY, which resulted in decreased proliferation and induction of Bim-mediated apoptosis. BIIE 0246 26-34 BCL2 like 11 Homo sapiens 193-196 19497958-6 2009 Adrenergic sensitivity for activation of K+ secretion in the presence of Y2-NpR blockade by BIIE0246 was (EC50s) 2.9 +/- 1.2 nM for epi and 13.3 +/- 1.0 nM for norepinephrine, approximately fourfold greater than in the presence of PYY. BIIE 0246 92-100 peptide YY Cavia porcellus 231-234 19497958-10 2009 BIIE0246 addition increased secretagog-activated Isc, consistent with in vitro release of either PYY or NPY. BIIE 0246 0-8 peptide YY Cavia porcellus 97-100 18412629-4 2008 This effect was sensitive to the presence of the selective Y(2) receptor antagonist (BIIE0246, 1 microm), but was not affected by addition of TrkB-Fc or by a neutralizing antibody against brain-derived neurotrophic factor (BDNF). BIIE 0246 85-93 neuropeptide Y receptor Y2 Mus musculus 59-72 19892938-6 2010 PYY suppression of intraperitoneal 5-hydroxytryptophan induced FPO and diarrhea was blocked by the Y(2) antagonist, BIIE0246, injected intraperitoneally and mimicked by PYY(3-36), but not [Leu(31),Pro(34)]NPY. BIIE 0246 116-124 peptide YY Mus musculus 0-3 19892938-6 2010 PYY suppression of intraperitoneal 5-hydroxytryptophan induced FPO and diarrhea was blocked by the Y(2) antagonist, BIIE0246, injected intraperitoneally and mimicked by PYY(3-36), but not [Leu(31),Pro(34)]NPY. BIIE 0246 116-124 peptide YY Mus musculus 169-172 19892938-6 2010 PYY suppression of intraperitoneal 5-hydroxytryptophan induced FPO and diarrhea was blocked by the Y(2) antagonist, BIIE0246, injected intraperitoneally and mimicked by PYY(3-36), but not [Leu(31),Pro(34)]NPY. BIIE 0246 116-124 neuropeptide Y Mus musculus 205-208 19119448-10 2008 BIIE0246, an antagonist for NPY Y(2) receptor, attenuated the suppression of ANP release by PYY. BIIE 0246 0-8 neuropeptide Y receptor Y2 Homo sapiens 28-45 19119448-10 2008 BIIE0246, an antagonist for NPY Y(2) receptor, attenuated the suppression of ANP release by PYY. BIIE 0246 0-8 natriuretic peptide A Homo sapiens 77-80 19119448-10 2008 BIIE0246, an antagonist for NPY Y(2) receptor, attenuated the suppression of ANP release by PYY. BIIE 0246 0-8 peptide YY Homo sapiens 92-95 17976913-9 2008 NPY inhibition of SNI-induced Fos expression was localized to the sural (uninjured) innervation territory, and could be blocked by intrathecal BIBO3304 and BIIE0246. BIIE 0246 156-164 neuropeptide Y Rattus norvegicus 0-3 17976913-9 2008 NPY inhibition of SNI-induced Fos expression was localized to the sural (uninjured) innervation territory, and could be blocked by intrathecal BIBO3304 and BIIE0246. BIIE 0246 156-164 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 30-33 18005069-10 2007 Y2 receptor blockade (1 microm BIIE0246) reversed the anticonvulsant effect of NPY but did not prevent NPY-induced increases in hippocampal dopamine. BIIE 0246 31-39 neuropeptide Y Rattus norvegicus 79-82 17382974-8 2007 The Y2 antagonist BIIE0246 produced an attenuation of both the NPY and PYY3-36 induced enhancement while the Y1 antagonist BIBO3304 and theY5 antagonist CGP71683A failed to alter the NPY or PYY3-36 induced enhancement. BIIE 0246 18-26 neuropeptide Y Rattus norvegicus 63-66 16959374-0 2006 Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze. BIIE 0246 78-86 neuropeptide Y receptor Y2 Rattus norvegicus 40-66 17240481-7 2007 BIIE0246, a specific Y(2) antagonist, displaced (125)I-PYY(3-36) binding to rGIR with high affinity (95nM). BIIE 0246 0-8 peptide YY Rattus norvegicus 55-58 17240481-7 2007 BIIE0246, a specific Y(2) antagonist, displaced (125)I-PYY(3-36) binding to rGIR with high affinity (95nM). BIIE 0246 0-8 G protein-coupled receptor 83 Rattus norvegicus 76-80 17240481-8 2007 Activation of (35)S-GTPgammaS binding by Y(2)-selective agonist in rGIR transfected cells was also completely abolished by BIIE0246. BIIE 0246 123-131 G protein-coupled receptor 83 Rattus norvegicus 67-71 17143304-11 2007 The Y2 receptor antagonist, BIIE0246, enhanced the inhibitory NPY effects. BIIE 0246 28-36 neuropeptide Y Rattus norvegicus 62-65 16100526-12 2005 The enhanced veratridine response observed in +/+ tissue following BIIE0246, indicates that Y(2) receptors are located on submucosal neurons and that their activation by NPY will inhibit enteric noncholinergic secretory neurotransmission. BIIE 0246 67-75 neuropeptide Y Mus musculus 170-173 16081487-9 2005 In addition, compared to baseline, BIIE0246 infusion resulted in increased plasma neuropeptide Y concentration in females (P < 0.05), while there was no observable change in males. BIIE 0246 35-43 neuropeptide Y Rattus norvegicus 82-96 17056830-3 2006 Counteracting the inhibiting effect of neuropeptide Y by the specific neuropeptide Y2 antagonist, BIIE0246, we expected occurrence of ventricular fibrillation in association with repeated periods of myocardial ischemia-reperfusion to decrease. BIIE 0246 98-106 neuropeptide Y Sus scrofa 39-53 16160600-5 2005 The significance of the NPY Y2 receptor was revealed by performing experiments before and after administration of its specific receptor antagonist BIIE0246. BIIE 0246 147-155 neuropeptide Y Canis lupus familiaris 24-27 15932924-7 2005 Conversely, BIIE0246 (a Y2 receptor antagonist) completely blocked the anorexigenic effects of PYY(3-36NH2) (P < 0.001), but had no effect on Ex4-induced satiety. BIIE 0246 12-20 neuropeptide Y receptor Y2 Mus musculus 24-35 16190896-2 2005 In hippocampal slices from rats and several wild-type mice, a Y2-preferring agonist mimicked, and the Y2-specific antagonist BIIE0246 blocked, the NPY-mediated inhibition both of glutamatergic transmission and of epileptiform discharges in two different slice models of temporal lobe epilepsy, stimulus train-induced bursting (STIB) and 0-Mg2+ bursting. BIIE 0246 125-133 neuropeptide Y Mus musculus 147-150 15857613-7 2005 The selective Y(2) antagonist BIIE0246 competitively inhibited NPY-mediated Ca(2+) transients in SMS-KAN/Gq(i9) cells with a pA(2) value of 7.39+/-0.1. BIIE 0246 30-38 neuropeptide Y Homo sapiens 63-66 15927700-8 2005 The enhancement of the NPY induced increase in DOPA accumulation observed by BIBO3304 was attenuated when examined in the presence of the Y2 antagonist BIIE0246. BIIE 0246 152-160 neuropeptide Y Rattus norvegicus 23-26 15670655-0 2005 Suppression of ethanol self-administration by the neuropeptide Y (NPY) Y2 receptor antagonist BIIE0246: evidence for sensitization in rats with a history of dependence. BIIE 0246 94-102 neuropeptide Y receptor Y2 Rattus norvegicus 50-82 15862527-0 2005 Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. BIIE 0246 72-80 neuropeptide Y receptor Y2 Rattus norvegicus 16-42 15862527-0 2005 Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. BIIE 0246 72-80 peptide YY Rattus norvegicus 131-141 15862527-5 2005 We found that pre-treatment with BIIE0246 (1 nmol) into the ARC attenuated the reduction in feeding observed following intraperitoneal injection of PYY((3-36)) (7.5 nmol/kg) (0-1 h food intake: BIIE0246/PYY((3-36)): 3.8 +/- 0.4 g; vs. Vehicle/PYY((3-36)): 2.7 +/- 0.2 g; P < 0.05). BIIE 0246 33-41 peptide YY Rattus norvegicus 148-151 15862527-5 2005 We found that pre-treatment with BIIE0246 (1 nmol) into the ARC attenuated the reduction in feeding observed following intraperitoneal injection of PYY((3-36)) (7.5 nmol/kg) (0-1 h food intake: BIIE0246/PYY((3-36)): 3.8 +/- 0.4 g; vs. Vehicle/PYY((3-36)): 2.7 +/- 0.2 g; P < 0.05). BIIE 0246 33-41 peptide YY Rattus norvegicus 203-206 15862527-5 2005 We found that pre-treatment with BIIE0246 (1 nmol) into the ARC attenuated the reduction in feeding observed following intraperitoneal injection of PYY((3-36)) (7.5 nmol/kg) (0-1 h food intake: BIIE0246/PYY((3-36)): 3.8 +/- 0.4 g; vs. Vehicle/PYY((3-36)): 2.7 +/- 0.2 g; P < 0.05). BIIE 0246 33-41 peptide YY Rattus norvegicus 203-206 15103451-8 2004 This effect was prevented by the NPY-Y(2)-receptor antagonist BIIE 0246 (0.1 micromol/l) but not by the NPY-Y(1)-receptor antagonist BIBP 3226 (10 micromol/l). BIIE 0246 62-71 neuropeptide Y receptor Y2 Homo sapiens 33-50 12967946-7 2003 The inhibitory effect on DeltaPI was reduced in the presence of the NPY Y2 antagonist, BIIE0246. BIIE 0246 87-95 neuropeptide Y Mus musculus 68-71 14984805-2 2004 Before the administration of formalin, NPY dose dependently increased blood pressure, an effect that could be prevented with the coadministration of the Y2 antagonist, BIIE0246. BIIE 0246 168-176 neuropeptide Y Rattus norvegicus 39-42 12855401-11 2003 Pretreatment with the NPY-Y2 receptor antagonist BIIE-0246 (120 pmol) in the PVN had no significant effect. BIIE 0246 49-58 neuropeptide Y Rattus norvegicus 22-25 12970079-11 2003 When the Y2 receptor antagonist BIIE0246 was given alone, it was not able to significantly affect the PYY(3-36)-induced response, whereas the Y1 receptor antagonist BIBO3304 partially (P<0.001) inhibited the decrease in blood flow evoked by PYY(3-36) at the highest dose. BIIE 0246 32-40 neuropeptide Y receptor Y2 Mus musculus 9-20 12967946-9 2003 Following administration of BIIE0246 in GAL-1R-KO mice, the inhibition of DeltaPI that followed stimulation of the sympathetic nerve was abolished. BIIE 0246 28-36 galanin and GMAP prepropeptide Mus musculus 40-43 12740867-8 2003 Both Y(2) and Y(5) receptor antagonists (respectively, 1 microM BIIE0246 and 1 microM CGP71683A) prevented this effect, suggesting the involvement of both receptor types. BIIE 0246 64-72 neuropeptide Y receptor Y5 Rattus norvegicus 14-27 12623227-2 2003 The KCl-evoked release of glutamate from hippocampal synaptosomes was inhibited by 1 microM NPY and this effect was insensitive to either BIBP3226 (Y1 receptor antagonist) or L-152,804 (Y5 receptor antagonist), but was sensitive to BIIE0246 (Y2 receptor antagonist). BIIE 0246 232-240 neuropeptide Y Rattus norvegicus 92-95 12813010-7 2003 Neither antagonist altered muscle tone; however, BIIE0246 blocked NPY and PYY(3-36) increases in Y(2)+/+ basal tone. BIIE 0246 49-57 neuropeptide Y Mus musculus 66-69 12813010-7 2003 Neither antagonist altered muscle tone; however, BIIE0246 blocked NPY and PYY(3-36) increases in Y(2)+/+ basal tone. BIIE 0246 49-57 peptide YY Mus musculus 74-77 11934810-8 2002 However, in the presence of BIIE 0246, a highly selective non-peptide NPY Y2-receptor antagonist, NPY was unable to increase 4-AP I(to) density. BIIE 0246 28-37 neuropeptide Y Rattus norvegicus 70-73 11997008-1 2002 The neuropeptide Y (NPY) receptor Y2 antagonist BIIE0246 has sub-nanomolar affinity for the human Y2 (hY2) receptor but binds very poorly to chicken Y2 (chY2) with micromolar affinity. BIIE 0246 48-56 neuropeptide Y receptor Y2 Homo sapiens 4-36 11997008-3 2002 Reciprocal mutagenesis between hY2 and chY2 revealed that three of these, individually and in combination, are important for BIIE0246 binding, namely positions Gln(135) in transmembrane (TM) 3, Leu(227) in TM5, and Leu(284) in TM6. BIIE 0246 125-133 tropomyosin 3 Homo sapiens 206-209 12568129-7 2002 Exposure of tissues to 1 microM BIIE 0246 almost completely prevented the suppression of double peaked constrictions by NPY (13-36) (10 nM) or by NPY (10 nM). BIIE 0246 32-41 neuropeptide Y Canis lupus familiaris 120-123 12568129-7 2002 Exposure of tissues to 1 microM BIIE 0246 almost completely prevented the suppression of double peaked constrictions by NPY (13-36) (10 nM) or by NPY (10 nM). BIIE 0246 32-41 neuropeptide Y Canis lupus familiaris 146-149 12377370-4 2002 Here, we examined the effects of a selective NPY-Y2 receptor antagonist, BIIE0246, on operant responding for ethanol in a sweetened solution, or the sweetened solution without ethanol, during 30 min sessions of free choice between the two. BIIE 0246 73-81 neuropeptide Y Rattus norvegicus 45-48 12055128-9 2002 BIIE0246 (100 nM) completely suppressed the actions of NPY and [ahx(5-24)]NPY in this model. BIIE 0246 0-8 neuropeptide Y Rattus norvegicus 55-58 12055128-9 2002 BIIE0246 (100 nM) completely suppressed the actions of NPY and [ahx(5-24)]NPY in this model. BIIE 0246 0-8 neuropeptide Y Rattus norvegicus 74-77 12055128-11 2002 BIIE0246 potently suppresses NPY actions in rat hippocampus, suggesting a dominant role for Y(2)R there. BIIE 0246 0-8 neuropeptide Y Rattus norvegicus 29-32 11934810-8 2002 However, in the presence of BIIE 0246, a highly selective non-peptide NPY Y2-receptor antagonist, NPY was unable to increase 4-AP I(to) density. BIIE 0246 28-37 neuropeptide Y Rattus norvegicus 98-101 11819028-1 2002 This study investigated the effects of BIIE0246, a novel neuropeptide Y (NPY) Y(2) receptor antagonist, on renal sympathetic nerve-evoked release of noradrenaline and NPY-like immunoreactivity (-LI) in the pig in vivo. BIIE 0246 39-47 neuropeptide Y Sus scrofa 73-76 11906964-12 2002 The Y(2) antagonist, BIIE0246 also raised basal I(sc) levels and attenuated subsequent PYY(3 - 36) but not Pro(34)PYY or hPP responses. BIIE 0246 21-29 peptide YY Homo sapiens 87-90 11589515-3 2001 Furthermore, the PYY-evoked splenic vasoconstrictor response was partially antagonized by BIIE0246 and subsequently almost abolished by the addition of H 409/22. BIIE 0246 90-98 peptide YY Sus scrofa 17-20 11819028-4 2002 BIIE0246 (100 nmol/kg) abolished the inhibitory effect of PYY. BIIE 0246 0-8 peptide YY Sus scrofa 58-61 11487518-0 2001 Vascular pharmacology of BIIE0246, the first selective non-peptide neuropeptide Y Y(2) receptor antagonist, in vivo. BIIE 0246 25-33 neuropeptide Y receptor Y2 Sus scrofa 67-95 11487518-1 2001 BIIE0246, a recently introduced non-peptide neuropeptide Y (NPY) Y(2) receptor antagonist, was pharmacologically characterized in vivo, on vascular responses evoked in the anaesthetized pig. BIIE 0246 0-8 neuropeptide Y receptor Y2 Sus scrofa 44-78 11487518-8 2001 Already 30 min after the last dose of BIIE0246 there was a significant recovery of the PYY-evoked splenic vasoconstriction, and a further 60 min later, this response was no longer significantly inhibited compared to control. BIIE 0246 38-46 peptide YY Sus scrofa 87-90 11487518-10 2001 It is concluded that BIIE0246 is a highly potent and selective NPY Y(2) receptor antagonist, albeit with rather short duration of action, in vivo. BIIE 0246 21-29 neuropeptide Y receptor Y2 Sus scrofa 63-80 11487518-11 2001 BIIE0246 thus represents the first interesting tool for studies on NPY Y(2) receptor-mediated transmission in vivo. BIIE 0246 0-8 neuropeptide Y receptor Y2 Sus scrofa 67-84 34576305-6 2021 As such, prior administration of the Y2 receptor antagonist BIIE0246 (0.2 nmol/0.2 muL/side) but not the Y1 receptor antagonist BIBO3304 trifluoroacetate (0.2 nmol/0.2 muL/side) blocked the effects of NPY in the DLS. BIIE 0246 60-68 neuropeptide Y receptor Y2 Mus musculus 37-48 10725255-0 2000 BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist. BIIE 0246 0-8 neuropeptide Y receptor Y2 Rattus norvegicus 52-80 10725255-2 2000 BIIE0246, a newly synthesized non-peptide neuropeptide Y (NPY) Y(2) receptor antagonist, was able to compete with high affinity (8 to 15 nM) for specific [(125)I]PYY(3 - 36) binding sites in HEK293 cells transfected with the rat Y(2) receptor cDNA, and in rat brain and human frontal cortex membrane homogenates. BIIE 0246 0-8 neuropeptide Y receptor Y2 Homo sapiens 42-76 10725255-9 2000 In the rat colon (a Y(2)/Y(4) bioassay), BIIE0246 (1 microM) completely blocked the contraction induced by PYY(3 - 36), but not that of [Leu(31), Pro(34)]NPY (a Y(1), Y(4) and Y(5) agonist) and hPP (a Y(4) and Y(5) agonist). BIIE 0246 41-49 neuropeptide Y Rattus norvegicus 154-157 11408607-6 2001 BIIE0246 completely abolished the inhibition of cAMP production by PYY in crypt cells and transfected CHO cells. BIIE 0246 0-8 peptide YY Cricetulus griseus 67-70 11287100-5 2001 A combination of BIBO3304 and BIIE0246 also partially attenuated hPP responses, leaving residual effects that were most probably Y(4)-mediated. BIIE 0246 30-38 familial progressive hyperpigmentation 1 Homo sapiens 65-68 11181427-2 2001 This study investigated the effects of BIIE0246, a novel neuropeptide Y (NPY) Y2 receptor antagonist, on the inhibition of cholinergic neuroeffector transmission in rat heart and guinea-pig trachea and purinergic neuroeffector transmission in guinea-pig vas deferens produced by the NPY Y2 receptor agonist, N-acetyl [Leu28,31] NPY 24-36. BIIE 0246 39-47 neuropeptide Y receptor Y2 Rattus norvegicus 57-89 34576305-6 2021 As such, prior administration of the Y2 receptor antagonist BIIE0246 (0.2 nmol/0.2 muL/side) but not the Y1 receptor antagonist BIBO3304 trifluoroacetate (0.2 nmol/0.2 muL/side) blocked the effects of NPY in the DLS. BIIE 0246 60-68 neuropeptide Y Mus musculus 201-204 33617904-6 2021 In STZ-induced diabetic mice, injection of the NPY Y2 receptor antagonist BIIE 0246 into BLA restored social novelty preference, whereas injection of BIIE 0246 into vHC was without effect. BIIE 0246 74-83 neuropeptide Y receptor Y2 Mus musculus 47-62 31771994-3 2020 The inhibitory Y2 receptor is expressed on mouse primary afferents, and intrathecal administration of the Y2 agonist peptide YY (PYY)3-36 reduced scratch episode frequency and duration induced by compound 48/80, an effect that could be reversed by intrathecal preadministration of the Y2 antagonist BIIE0246. BIIE 0246 299-307 neuropeptide Y receptor Y2 Mus musculus 15-26 33197050-6 2021 Injection of the NPY Y2 receptor agonist NPY 13-36 into naive mice impaired social novelty preference, but not sociability, and this effect was inhibited by the NPY Y2 receptor antagonist BIIE 0246. BIIE 0246 188-197 neuropeptide Y receptor Y2 Mus musculus 17-32 33197050-6 2021 Injection of the NPY Y2 receptor agonist NPY 13-36 into naive mice impaired social novelty preference, but not sociability, and this effect was inhibited by the NPY Y2 receptor antagonist BIIE 0246. BIIE 0246 188-197 neuropeptide Y receptor Y2 Mus musculus 161-176 32535011-6 2020 In the MeA, on the other hand, BIIE0246, but not BIBO3304 trifluoroacetate blocked the effects of NPY. BIIE 0246 31-39 neuropeptide Y Mus musculus 98-101 27995104-9 2016 Administration of BIIE0246 significantly reduced serum VEGF and VEGF: sVEGFR-1 ratio and increased serum sVEGFR-1 concentrations in obese animals (P < 0.05). BIIE 0246 18-26 vascular endothelial growth factor A Mus musculus 55-59 31736656-6 2019 Y2R agonist PYY (3-36) mimicked and Y2R antagonist BIIE0246 abolished the NPY effects in the mPFC. BIIE 0246 51-59 neuropeptide Y Rattus norvegicus 74-77 29852245-7 2018 This effect was diminished by both Y1 (BIBO3304) and Y2 (BIIE0246) receptor antagonists, indicating that both receptors participate in mediating the antinociceptive effect of NPY. BIIE 0246 57-65 neuropeptide Y Rattus norvegicus 175-178 29674968-0 2018 Peripherally Administered Y2-Receptor Antagonist BIIE0246 Prevents Diet-Induced Obesity in Mice With Excess Neuropeptide Y, but Enhances Obesity in Control Mice. BIIE 0246 49-57 neuropeptide Y receptor Y2 Mus musculus 26-37 29674968-0 2018 Peripherally Administered Y2-Receptor Antagonist BIIE0246 Prevents Diet-Induced Obesity in Mice With Excess Neuropeptide Y, but Enhances Obesity in Control Mice. BIIE 0246 49-57 neuropeptide Y Mus musculus 108-122 29674968-5 2018 Specific Y2-receptor antagonist, BIIE0246, was administered (1.3 mg/kg/day, i.p.) BIIE 0246 33-41 neuropeptide Y receptor Y2 Mus musculus 9-20 29157865-11 2018 Finally, the co-infusion of the Y2 receptor (Y2R) antagonist BIIE0246 with PYY (3-36) abolished the [Ca2+]i increase induced by the peptide, suggesting that PYY (3-36)-induced [Ca2+]i increase in hippocampal neurons occurs via Y2Rs. BIIE 0246 61-69 peptide YY Homo sapiens 75-78 29157865-11 2018 Finally, the co-infusion of the Y2 receptor (Y2R) antagonist BIIE0246 with PYY (3-36) abolished the [Ca2+]i increase induced by the peptide, suggesting that PYY (3-36)-induced [Ca2+]i increase in hippocampal neurons occurs via Y2Rs. BIIE 0246 61-69 peptide YY Homo sapiens 157-160 27995104-9 2016 Administration of BIIE0246 significantly reduced serum VEGF and VEGF: sVEGFR-1 ratio and increased serum sVEGFR-1 concentrations in obese animals (P < 0.05). BIIE 0246 18-26 vascular endothelial growth factor A Mus musculus 64-68 27995104-10 2016 In normal animals, BIIE0246 increased serum sVEGFR-1 level and decreased VEGF: sVEGFR-1 ratio. BIIE 0246 19-27 vascular endothelial growth factor A Mus musculus 45-49 26153206-8 2015 Half of the control and the obese animals received 1 microM, 100 microL/kg NPY Y2 receptor antagonist (BIIE 0246) intraperitoneally. BIIE 0246 103-112 neuropeptide Y receptor Y2 Mus musculus 75-90